HB 7 authorizes Maryland's State Board of Examiners to issue limited licenses for music therapists who are completing full licensing requirements but lack sufficient clinical experience. This directly affects new music therapists and healthcare facilities needing to hire them under supervision while they fulfill certification steps. The bill creates a 1-year limited license (renewable once) requiring direct supervision by a fully licensed music therapist, with a 2-year deadline to obtain full licensure. It explicitly states limited licenses cannot replace services from audiologists or speech-language pathologists. The policy change streamlines entry into the profession without altering existing practice standards for music therapy.
HB 393 requires health insurers, nonprofit health plans, HMOs, and managed care organizations in Maryland to cover scalp cooling systems when they provide coverage for chemotherapy treatments for cancer. This applies directly to cancer patients undergoing chemotherapy who use scalp cooling to prevent hair loss, and to the insurers that must now include this coverage. The bill defines scalp cooling systems as medical devices designed for repeated use to preserve hair during cancer treatment. Coverage must be provided for these systems as part of chemotherapy treatment plans, effective January 1, 2027. The law amends Maryland’s Insurance Article (Section 15-864) to mandate this coverage for qualifying health plans.
SB 385 (The Vax Act) requires Maryland’s Secretary of Health to issue evidence-based recommendations for immunizations, screenings, and preventive services, aligning with guidance from major medical organizations like the CDC and U.S. Preventive Services Task Force. It expands pharmacists’ authority to administer vaccines (including those recommended by CDC or the Secretary) to patients aged 3+ after completing specific training and certification, while mandating health insurers to cover these services without cost-sharing. The bill also repeals outdated pertussis-related provisions and updates reporting requirements for pharmacists. This directly affects pharmacists, health insurers, and patients seeking preventive care, aiming to improve access to vaccinations and screenings.
SB 333 creates the Interstate Podiatric Medical Licensure Compact, allowing podiatrists (foot and ankle specialists) licensed in Maryland to practice in other participating states more easily. The bill establishes a streamlined process for obtaining an "expedited license" in multiple states without altering existing state licensing laws, requiring podiatrists to pass national exams and pass background checks. Crucially, it mandates that podiatrists follow the rules of the state where the patient is located during treatment, not where the provider is licensed. This compact directly affects licensed podiatrists seeking multi-state practice and state licensing boards overseeing medical practice.
HB 442 requires nursing homes, assisted living facilities, and nurse midwives in Maryland to disclose their professional liability insurance status to residents and potential residents. Specifically, these providers must provide written notice (including electronic communication) if they lack coverage or if coverage has lapsed and not been renewed, with timing requirements: at the first visit for potential residents or at application for admission, and within 30 days of a lapse for current residents. The bill also mandates that facilities without coverage post a conspicuous notice for residents and guests. This law does not change insurance requirements but ensures transparency about coverage gaps. It directly affects residents and potential residents of these care facilities by providing clear, timely disclosure of insurance status.
HB 637 ("The Vax Act") requires Maryland's Secretary of Health to issue science-based recommendations for immunizations, screenings, and preventive services using guidance from major medical organizations like the CDC and American Academy of Pediatrics. It expands pharmacists' authority to administer flu, COVID-19, and emergency vaccines to patients aged 3 and older (previously limited to 18+ for some vaccines) after completing specific training. The bill also mandates that health insurance plans cover these recommended services without cost-sharing for patients. This directly affects pharmacists, health insurers, and Maryland residents seeking preventive care, particularly children and adults needing routine vaccinations.
HB 1117 requires Maryland's Medicaid program (Maryland Medical Assistance Program) and certain insurers to cover approved "elopement response devices" for specific individuals. These devices - such as door sensors, wearable location trackers, or alert systems - prevent people with cognitive, developmental, or neurological conditions from wandering unsafely (e.g., leaving a supervised area without the ability to return safely). Coverage is mandated when ordered by a qualified healthcare provider and documented in a qualifying plan (like an individualized education plan or dementia care plan) for eligible recipients: those under 21 with early screening eligibility, on home-based waiver programs, or diagnosed with Alzheimer’s/dementia. The bill defines these devices as medical equipment or assistive technology under state programs, ensuring coverage without regard to when the program was established.
HB 1292 requires child advocacy centers in Maryland to ensure all health care professionals providing medical or mental health services are properly licensed or certified and work within their scope of practice. It mandates that centers establish a "continuity of care plan" to notify families when providers change, including contact information for both new and former providers, and allows former providers to assist with care transitions per professional standards. Centers must report specific violations to health occupations boards or the Governor’s Office of Crime Prevention and Policy, and the Governor’s Office must publish annual data about child advocacy centers online. This bill directly affects child advocacy centers, their health care staff, and the children and families receiving services at these centers.
This bill requires health insurers and health plans in Maryland to cover salpingectomy (surgery to remove fallopian tubes) specifically for ovarian cancer prevention as a standard benefit, with no out-of-pocket costs like copays or deductibles for patients. It applies to all health insurance policies issued in Maryland after January 1, 2027, directly affecting women who might choose this preventive surgery and the insurers providing coverage. The key provision bans cost-sharing for this procedure, except when an individual is enrolled in a high-deductible health plan meeting federal criteria. This ensures access to a proven preventive measure without financial barriers for most patients.
HB 1426 creates a new permit for clinical research pharmacies in Maryland, which are facilities specifically designed to conduct clinical trials. It allows healthcare providers to own these pharmacies under strict conditions, including requiring a licensed pharmacist to be on-site during all operating hours and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations or entities from being classified as "practice of medicine," meaning trial staff no longer need individual medical licenses for their trial-related work. This change aims to streamline clinical research by removing a regulatory barrier that previously required individual licensing for trial staff.
